Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.19.3
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2019
Aug. 31, 2019
May 31, 2016
Commitments and Contingencies [Line Items]      
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years  
Payment to acquire other assets     $ 1,500,000
Minimum      
Commitments and Contingencies [Line Items]      
Royalty on every net sales   0.75%  
Maximum      
Commitments and Contingencies [Line Items]      
Royalty on every net sales   2.00%  
Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years  
Minimum annual license maintenance fees   $ 150,000  
Project Work Order | Termination of Any One Clinical Trial      
Commitments and Contingencies [Line Items]      
Financial penalties   8,300,000  
Project Work Order | Termination of Any One Clinical Trial | Minimum      
Commitments and Contingencies [Line Items]      
Financial penalties   700,000  
Project Work Order | Termination of All Clinical Trials | Minimum      
Commitments and Contingencies [Line Items]      
Financial penalties   500,000  
Project Work Order | Termination of All Clinical Trials | Maximum      
Commitments and Contingencies [Line Items]      
Financial penalties   1,100,000  
Samsung Agreement [Member] | Manufacturing and Supply Service [Member]      
Commitments and Contingencies [Line Items]      
Supply Commitment Delivered $ 33,000,000    
Remaining Supply commitment Cost 60,000,000    
Obligation Due in Next Twelve Months 30,000,000    
Obligation Due in Next Two years $ 30,000,000    
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   500,000  
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   $ 5,000,000  
Royalty on every net sales   5.00%  
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   $ 500,000  
Royalty on every net sales   3.50%